The University of Chicago Header Logo

Samuel Hellman

Concepts (303)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Breast Neoplasms
26
2015
3029
1.340
Why?
Neoplasms
21
2023
3053
1.230
Why?
Neoplasm Metastasis
19
2016
1066
1.060
Why?
Radiotherapy
6
2014
321
0.670
Why?
Prostatic Neoplasms
9
2007
1757
0.660
Why?
Epigenesis, Genetic
1
2023
530
0.630
Why?
Antineoplastic Agents
8
2015
2347
0.490
Why?
Knowledge
1
2014
28
0.460
Why?
Neovascularization, Pathologic
6
2004
354
0.450
Why?
Education, Medical
2
2014
244
0.440
Why?
Models, Theoretical
3
2005
491
0.420
Why?
Physicians, Primary Care
1
2014
104
0.410
Why?
Randomized Controlled Trials as Topic
5
2004
863
0.400
Why?
Lymphatic Metastasis
8
2003
500
0.390
Why?
Humans
72
2023
91073
0.390
Why?
Physician-Patient Relations
4
2007
627
0.380
Why?
Radiation, Ionizing
4
2010
124
0.360
Why?
Radiation Oncology
3
1997
122
0.340
Why?
Human Experimentation
1
2010
39
0.330
Why?
Nucleoside-Diphosphate Kinase
2
2000
12
0.330
Why?
Ethics, Research
1
2010
52
0.330
Why?
Disease-Free Survival
12
2011
1169
0.320
Why?
Monomeric GTP-Binding Proteins
2
2000
19
0.320
Why?
Patient Advocacy
3
2015
54
0.310
Why?
MicroRNAs
4
2015
568
0.300
Why?
Physician's Role
4
2005
177
0.290
Why?
Chemotherapy, Adjuvant
8
2005
478
0.290
Why?
Genetic Therapy
9
2008
375
0.280
Why?
Models, Economic
1
2007
63
0.280
Why?
Hematopoiesis
1
2008
170
0.280
Why?
Neoplasm Recurrence, Local
5
2005
1374
0.270
Why?
Neoplastic Stem Cells
1
2008
163
0.260
Why?
Decision Making
3
2007
675
0.260
Why?
Tumor Necrosis Factor-alpha
7
2008
705
0.260
Why?
Liver Neoplasms
3
2018
763
0.260
Why?
Prostatectomy
3
2007
476
0.260
Why?
Hematopoietic Stem Cells
1
2008
308
0.250
Why?
Androgen Antagonists
2
2005
139
0.250
Why?
Prognosis
11
2005
3825
0.250
Why?
Attitude of Health Personnel
2
2005
652
0.250
Why?
Transcription Factors
6
2004
1671
0.240
Why?
Antineoplastic Agents, Hormonal
2
2003
145
0.240
Why?
Ethics, Medical
3
2000
307
0.240
Why?
Prostate-Specific Antigen
2
1998
343
0.240
Why?
Colorectal Neoplasms
3
2018
977
0.230
Why?
Attitude to Health
1
2005
220
0.230
Why?
Nitriles
1
2004
157
0.220
Why?
Triazoles
1
2004
107
0.210
Why?
Biomedical Research
3
2014
401
0.210
Why?
Epithelial-Mesenchymal Transition
1
2023
99
0.210
Why?
History, 20th Century
3
2010
316
0.210
Why?
Sentinel Lymph Node Biopsy
1
2003
80
0.200
Why?
Managed Care Programs
2
2000
41
0.200
Why?
Brachytherapy
1
2003
121
0.200
Why?
Disease Progression
8
2012
1493
0.190
Why?
Melanoma
2
2013
475
0.190
Why?
Proliferating Cell Nuclear Antigen
2
2000
67
0.190
Why?
Lymph Node Excision
1
2003
222
0.180
Why?
Lymph Nodes
4
2000
554
0.180
Why?
Biomarkers, Tumor
3
2003
1559
0.180
Why?
Aged
16
2018
19574
0.180
Why?
Carcinoma
1
2003
438
0.170
Why?
Medical Oncology
2
2014
390
0.170
Why?
Female
31
2018
47186
0.170
Why?
Survival Analysis
6
2013
1500
0.170
Why?
Combined Modality Therapy
9
2005
1713
0.170
Why?
Clinical Trials as Topic
4
2014
1144
0.160
Why?
Cadherins
1
2000
165
0.160
Why?
Skin Neoplasms
1
2004
603
0.160
Why?
Radiosurgery
2
2013
286
0.160
Why?
Middle Aged
16
2018
26555
0.150
Why?
Mammography
2
2000
470
0.150
Why?
Radiotherapy, Adjuvant
4
2005
291
0.150
Why?
Gene Amplification
1
2018
135
0.150
Why?
Immediate-Early Proteins
4
2004
164
0.130
Why?
History, 21st Century
2
2009
185
0.130
Why?
Quality of Health Care
1
2000
388
0.130
Why?
Mastectomy
2
2004
254
0.130
Why?
Antigens, Neoplasm
1
1998
342
0.130
Why?
Prescription Fees
1
2015
10
0.120
Why?
Consumer Advocacy
1
1995
10
0.120
Why?
Disease Models, Animal
4
2016
2416
0.120
Why?
Health Care Rationing
1
1996
83
0.120
Why?
Microcirculation
3
2000
105
0.120
Why?
Insurance Coverage
1
1996
126
0.120
Why?
Chromosomes, Human, Pair 14
1
2015
49
0.120
Why?
Aged, 80 and over
7
2018
6847
0.120
Why?
United States
7
2015
7188
0.120
Why?
Drug Costs
1
2015
67
0.120
Why?
Erectile Dysfunction
2
2007
76
0.120
Why?
Neoplasm Staging
5
2004
2022
0.110
Why?
Patients
1
1995
104
0.110
Why?
Medical Laboratory Science
1
1994
7
0.110
Why?
Radiotherapy, Computer-Assisted
2
2008
24
0.110
Why?
Clinical Medicine
1
1994
34
0.110
Why?
Life Expectancy
1
1994
88
0.110
Why?
Aging
1
1998
732
0.110
Why?
Genetic Engineering
1
1994
118
0.110
Why?
Patient Participation
1
2015
227
0.110
Why?
Urinary Incontinence
2
2007
216
0.110
Why?
Health Care Reform
1
1994
85
0.100
Why?
History, 19th Century
2
2009
56
0.100
Why?
Male
13
2018
43249
0.100
Why?
Adult
12
2018
27147
0.100
Why?
Data Interpretation, Statistical
2
2004
304
0.100
Why?
Treatment Outcome
6
2013
8436
0.090
Why?
Diagnostic Imaging
1
2015
475
0.090
Why?
Evidence-Based Medicine
2
2005
441
0.090
Why?
Age Factors
3
2007
1876
0.090
Why?
Neoplasm Transplantation
6
2016
397
0.090
Why?
Informed Consent
2
2010
277
0.090
Why?
Animals
15
2016
27783
0.090
Why?
Philosophy, Medical
2
2005
17
0.090
Why?
Multivariate Analysis
3
1998
982
0.090
Why?
Follow-Up Studies
4
2000
3716
0.090
Why?
Ohio
1
2010
41
0.090
Why?
Hodgkin Disease
1
1991
169
0.080
Why?
Tamoxifen
2
2004
167
0.080
Why?
NM23 Nucleoside Diphosphate Kinases
2
2000
7
0.080
Why?
Biological Evolution
1
1997
988
0.080
Why?
Research Subjects
1
2010
73
0.080
Why?
X-Ray Therapy
1
2008
6
0.080
Why?
Lung
2
2012
1310
0.080
Why?
Analysis of Variance
2
2004
897
0.080
Why?
Universities
1
2010
148
0.080
Why?
Lung Neoplasms
3
2013
2380
0.080
Why?
Cell Line, Tumor
5
2015
2615
0.080
Why?
Adenocarcinoma
3
2012
1183
0.080
Why?
Radiation-Sensitizing Agents
1
2008
97
0.080
Why?
Military Personnel
1
2010
93
0.080
Why?
Survival Rate
3
2012
1898
0.080
Why?
Radiotherapy, Conformal
1
2008
82
0.070
Why?
Melanoma, Experimental
1
2008
111
0.070
Why?
Philosophy
1
2007
9
0.070
Why?
Rectal Diseases
1
2007
23
0.070
Why?
Urethral Stricture
1
2007
14
0.070
Why?
Practice Patterns, Physicians'
1
1993
608
0.070
Why?
Critical Pathways
1
2007
37
0.070
Why?
DNA-Binding Proteins
4
2004
1248
0.070
Why?
Actuarial Analysis
2
1997
66
0.070
Why?
Mutation
1
2018
4203
0.070
Why?
Time Factors
4
2005
5378
0.070
Why?
Phenotype
3
2015
2480
0.060
Why?
Fund Raising
1
2005
2
0.060
Why?
Academies and Institutes
1
2006
33
0.060
Why?
Gene Expression Regulation
3
2002
1993
0.060
Why?
Predictive Value of Tests
3
2003
1750
0.060
Why?
Dermatology
1
2006
41
0.060
Why?
Immunohistochemistry
3
2000
1806
0.060
Why?
Gene Expression Profiling
3
2018
1465
0.060
Why?
Trastuzumab
1
2005
77
0.060
Why?
Heterografts
2
2015
105
0.060
Why?
Sample Size
1
2005
125
0.060
Why?
Mastectomy, Radical
2
1995
10
0.060
Why?
Drug Administration Schedule
2
2003
866
0.060
Why?
Patient Satisfaction
1
2007
464
0.060
Why?
Antibiotics, Antineoplastic
1
2004
111
0.060
Why?
Radiation Dosage
2
2011
232
0.050
Why?
Databases, Factual
1
2007
882
0.050
Why?
Doxorubicin
1
2004
294
0.050
Why?
Antineoplastic Combined Chemotherapy Protocols
3
2004
2550
0.050
Why?
Carcinoma, Lewis Lung
2
2000
24
0.050
Why?
Cell Transformation, Neoplastic
1
2005
455
0.050
Why?
Neoplasm Invasiveness
1
2004
570
0.050
Why?
Interdisciplinary Communication
1
2003
130
0.050
Why?
Mice
9
2015
11993
0.050
Why?
Surgical Procedures, Operative
1
2004
210
0.050
Why?
Kaplan-Meier Estimate
2
2018
854
0.050
Why?
Early Growth Response Protein 1
4
2004
57
0.050
Why?
Lymphedema
1
2003
79
0.050
Why?
Transcriptional Activation
1
2002
295
0.050
Why?
Sensitivity and Specificity
2
2003
2020
0.050
Why?
Risk
1
2003
657
0.050
Why?
Coumarins
1
2000
13
0.050
Why?
Dose-Response Relationship, Radiation
2
2000
187
0.050
Why?
Oligonucleotide Array Sequence Analysis
1
2003
694
0.040
Why?
Immunity, Cellular
1
2001
179
0.040
Why?
Tumor Cells, Cultured
5
2002
1049
0.040
Why?
Risk Assessment
2
2005
2345
0.040
Why?
Gene Expression
2
2015
1313
0.040
Why?
Cisplatin
1
2002
599
0.040
Why?
Databases as Topic
1
2000
94
0.040
Why?
Mice, Nude
5
2002
821
0.040
Why?
Cancer Vaccines
1
2001
164
0.040
Why?
Antibodies, Monoclonal, Humanized
1
2005
968
0.040
Why?
Carcinoma, Lobular
1
2000
81
0.040
Why?
Antibodies, Monoclonal
1
2005
1404
0.040
Why?
Apoptosis
3
2008
1723
0.040
Why?
Plasminogen
1
1998
45
0.040
Why?
Genetic Vectors
4
2004
448
0.040
Why?
Class II Phosphatidylinositol 3-Kinases
1
2018
9
0.040
Why?
Carcinoma, Ductal, Breast
1
2000
160
0.040
Why?
Research
2
2003
252
0.040
Why?
Transcription, Genetic
1
2002
1163
0.040
Why?
Receptor, Notch1
1
2018
94
0.040
Why?
Paraffin Embedding
1
1997
78
0.040
Why?
Severity of Illness Index
1
2003
1892
0.030
Why?
Mutagenesis
1
1997
202
0.030
Why?
Neoplasm Proteins
1
2000
538
0.030
Why?
Xenograft Model Antitumor Assays
2
2011
492
0.030
Why?
Axilla
1
1997
104
0.030
Why?
Adrenalectomy
1
1996
45
0.030
Why?
Peptide Fragments
1
1998
465
0.030
Why?
Ovariectomy
1
1996
83
0.030
Why?
Insurance, Health
1
1998
164
0.030
Why?
HCT116 Cells
1
2016
158
0.030
Why?
Researcher-Subject Relations
1
1996
4
0.030
Why?
Vascular Endothelial Growth Factor A
1
2018
409
0.030
Why?
Molecular Biology
1
1996
90
0.030
Why?
Social Responsibility
1
1996
57
0.030
Why?
Carcinoma, Non-Small-Cell Lung
1
2004
1132
0.030
Why?
Fibrosarcoma
1
1995
87
0.030
Why?
Immunotherapy
1
2001
702
0.030
Why?
Luminescent Measurements
1
2015
62
0.030
Why?
DNA Repair
1
1997
363
0.030
Why?
Radiotherapy Planning, Computer-Assisted
1
1996
188
0.030
Why?
Cell Nucleus
1
1997
607
0.030
Why?
Laryngeal Neoplasms
1
1995
89
0.030
Why?
Mice, Inbred NOD
1
2015
200
0.030
Why?
Algorithms
1
2003
1933
0.030
Why?
Likelihood Functions
1
1995
252
0.030
Why?
Mice, SCID
1
2015
260
0.030
Why?
Proportional Hazards Models
1
1996
852
0.030
Why?
Research Design
2
2003
594
0.030
Why?
Neoplasms, Experimental
1
1995
270
0.030
Why?
Tumor Burden
1
2015
316
0.030
Why?
Social Values
1
1994
44
0.030
Why?
Regression Analysis
1
1995
590
0.030
Why?
Socioeconomic Factors
1
1996
596
0.030
Why?
Diffusion of Innovation
1
1994
74
0.030
Why?
Receptors, Estrogen
1
1995
395
0.030
Why?
Genetic Diseases, Inborn
1
1994
101
0.030
Why?
Health Care Costs
1
1995
238
0.030
Why?
Patient-Centered Care
1
1995
214
0.030
Why?
Forecasting
1
1994
307
0.030
Why?
Imaging, Three-Dimensional
1
2016
606
0.030
Why?
Molecular Targeted Therapy
1
2014
282
0.020
Why?
Adenoviridae
2
2004
349
0.020
Why?
Social Change
1
1991
8
0.020
Why?
England
1
1991
38
0.020
Why?
Maximum Tolerated Dose
1
2011
265
0.020
Why?
Acquired Immunodeficiency Syndrome
1
1991
81
0.020
Why?
Cluster Analysis
1
2011
373
0.020
Why?
Costs and Cost Analysis
1
1991
153
0.020
Why?
Databases, Genetic
1
2011
270
0.020
Why?
Promoter Regions, Genetic
2
2004
964
0.020
Why?
Precision Medicine
1
2014
421
0.020
Why?
Carcinoma, Squamous Cell
1
1996
1095
0.020
Why?
Receptors, Tumor Necrosis Factor, Type II
1
2008
20
0.020
Why?
Etanercept
1
2008
33
0.020
Why?
Esophageal Neoplasms
2
2002
333
0.020
Why?
Receptors, Tumor Necrosis Factor, Type I
1
2008
44
0.020
Why?
Receptors, Tumor Necrosis Factor
1
2008
90
0.020
Why?
Health Knowledge, Attitudes, Practice
1
1993
538
0.020
Why?
Rats
2
2004
4043
0.020
Why?
Double-Blind Method
1
1991
1738
0.020
Why?
Immunoglobulin G
1
2008
476
0.020
Why?
Delivery of Health Care
1
1991
430
0.020
Why?
Gene Expression Regulation, Neoplastic
1
2011
1295
0.020
Why?
Retrospective Studies
1
2000
9399
0.020
Why?
Necrosis
2
1996
211
0.020
Why?
Endothelial Cells
1
2008
471
0.020
Why?
Reproducibility of Results
1
2011
2785
0.020
Why?
Pleural Effusion
1
2004
47
0.010
Why?
Organoplatinum Compounds
1
2004
94
0.010
Why?
Recombinant Fusion Proteins
2
1996
565
0.010
Why?
Acetylcysteine
1
2004
71
0.010
Why?
Biopsy, Needle
1
2004
233
0.010
Why?
Immunosuppressive Agents
1
2008
988
0.010
Why?
Genes, erbB-2
1
2003
25
0.010
Why?
Probability
1
2004
356
0.010
Why?
Selective Estrogen Receptor Modulators
1
2003
34
0.010
Why?
Receptors, Steroid
1
2003
42
0.010
Why?
Paclitaxel
1
2004
499
0.010
Why?
Mice, Inbred C57BL
2
2000
3303
0.010
Why?
DNA, Complementary
1
2002
391
0.010
Why?
Up-Regulation
1
2004
727
0.010
Why?
Phytotherapy
1
2003
136
0.010
Why?
Isocoumarins
1
2000
7
0.010
Why?
Umbilical Veins
1
2000
46
0.010
Why?
Drug Resistance, Neoplasm
1
2004
613
0.010
Why?
Laminin
1
2000
93
0.010
Why?
Drug Combinations
1
2000
205
0.010
Why?
ROC Curve
1
2003
785
0.010
Why?
Proteoglycans
1
2000
124
0.010
Why?
Mass Screening
1
2004
646
0.010
Why?
Angiostatins
1
1998
15
0.010
Why?
Collagen
1
2000
296
0.010
Why?
Cytokines
1
2003
817
0.010
Why?
Endothelium, Vascular
1
2000
435
0.010
Why?
Colonic Neoplasms
1
2002
572
0.010
Why?
Cohort Studies
1
2004
2904
0.010
Why?
Cell Movement
1
2000
793
0.010
Why?
Dose-Response Relationship, Drug
1
2000
1935
0.010
Why?
Biomarkers
1
2003
1814
0.010
Why?
Mastadenovirus
1
1995
4
0.010
Why?
Liposomes
1
1995
93
0.010
Why?
Cells, Cultured
1
2000
2891
0.010
Why?
Neoplasms, Radiation-Induced
1
1995
95
0.010
Why?
Radiation Tolerance
1
1995
173
0.010
Why?
Transplantation, Heterologous
1
1995
368
0.010
Why?
Thrombosis
1
1996
312
0.010
Why?
Signal Transduction
1
2003
3442
0.010
Why?
Hellman's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (303)
Explore
_
Co-Authors (25)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_
Physical Neighbors
_